SI1414809T1 - Derivati indan ocetne kisline in njihova uporaba kot farmacevtska sredstva, intermediati in postopek za pripravo - Google Patents

Derivati indan ocetne kisline in njihova uporaba kot farmacevtska sredstva, intermediati in postopek za pripravo

Info

Publication number
SI1414809T1
SI1414809T1 SI200230691T SI200230691T SI1414809T1 SI 1414809 T1 SI1414809 T1 SI 1414809T1 SI 200230691 T SI200230691 T SI 200230691T SI 200230691 T SI200230691 T SI 200230691T SI 1414809 T1 SI1414809 T1 SI 1414809T1
Authority
SI
Slovenia
Prior art keywords
intermediates
preparation
acetic acid
acid derivatives
pharmaceutical agents
Prior art date
Application number
SI200230691T
Other languages
English (en)
Inventor
Derek B Lowe
Philip L Wickens
Xin Ma
Mingbao Zhang
William H Bullock
Philip D G Coish
Ingo A Mugge
Andreas Stolle
Ming Wang
Yamin Wang
Chengzhi Zhang
Hai-Jun Zhang
Lei Zhu
Manami Tsutsumi
James N Livingston
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of SI1414809T1 publication Critical patent/SI1414809T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C07C51/44—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation by distillation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI200230691T 2001-07-27 2002-07-25 Derivati indan ocetne kisline in njihova uporaba kot farmacevtska sredstva, intermediati in postopek za pripravo SI1414809T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30850001P 2001-07-27 2001-07-27
US37304802P 2002-04-16 2002-04-16
EP02750297A EP1414809B1 (en) 2001-07-27 2002-07-25 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
PCT/US2002/023614 WO2003011842A1 (en) 2001-07-27 2002-07-25 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation

Publications (1)

Publication Number Publication Date
SI1414809T1 true SI1414809T1 (sl) 2008-08-31

Family

ID=26976280

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230691T SI1414809T1 (sl) 2001-07-27 2002-07-25 Derivati indan ocetne kisline in njihova uporaba kot farmacevtska sredstva, intermediati in postopek za pripravo

Country Status (33)

Country Link
US (4) US6828335B2 (sl)
EP (1) EP1414809B1 (sl)
JP (1) JP4510447B2 (sl)
KR (2) KR100956898B1 (sl)
CN (1) CN100528850C (sl)
AR (1) AR036237A1 (sl)
AT (1) ATE388944T1 (sl)
AU (2) AU2002319693B2 (sl)
BR (1) BR0211502A (sl)
CA (2) CA2455620C (sl)
CO (1) CO5560561A2 (sl)
CY (1) CY1107370T1 (sl)
DE (1) DE60225561T2 (sl)
DK (1) DK1414809T3 (sl)
ES (1) ES2302825T3 (sl)
HK (2) HK1073653A1 (sl)
HR (1) HRP20040076A2 (sl)
HU (1) HUP0700105A2 (sl)
IL (3) IL159960A0 (sl)
MA (1) MA27063A1 (sl)
MX (1) MXPA04000599A (sl)
MY (1) MY139541A (sl)
NO (2) NO20040356L (sl)
NZ (1) NZ531351A (sl)
PE (1) PE20030326A1 (sl)
PL (1) PL374383A1 (sl)
PT (1) PT1414809E (sl)
RU (1) RU2314298C2 (sl)
SI (1) SI1414809T1 (sl)
SV (1) SV2003001186A (sl)
TW (2) TWI328008B (sl)
UY (1) UY27392A1 (sl)
WO (1) WO2003011842A1 (sl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065129A1 (en) * 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AU2003263814A1 (en) * 2002-07-26 2004-02-16 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
WO2004058174A2 (en) * 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1752146A4 (en) * 2004-05-19 2007-10-10 Ajinomoto Kk THERAPEUTIC AGENT AGAINST DIABETES
CA2577668A1 (en) * 2004-08-20 2006-02-23 Cadila Healthcare Limited Novel antidiabetic compounds
JPWO2006057448A1 (ja) * 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体
WO2007114213A1 (ja) 2006-03-30 2007-10-11 Asahi Kasei Pharma Corporation 置換二環式環状誘導体及びその用途
GB0712653D0 (en) 2007-06-28 2007-08-08 Syngenta Ltd Novel herbicides
GB0717082D0 (en) 2007-09-03 2007-10-10 Syngenta Ltd Novel herbicides
CN104710365A (zh) 2008-04-28 2015-06-17 旭化成制药株式会社 苯丙酸衍生物及其用途
US8771724B2 (en) * 2008-06-23 2014-07-08 Toa Eiyo Ltd. Percutaneous absorption enhancer and transdermal preparation using the same
NZ592603A (en) * 2008-10-21 2013-02-22 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof
CA2749931C (en) * 2009-01-26 2018-03-06 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
TW201040154A (en) 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted indanes, process for preparation thereof and use thereof as a medicament
WO2010141690A2 (en) * 2009-06-04 2010-12-09 Dara Biosciences, Inc. Indane analogs and use as pharmaceutical agents and process of making
WO2010141696A1 (en) * 2009-06-04 2010-12-09 Dara Biosciences, Inc. Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
US20180200230A1 (en) * 2009-06-04 2018-07-19 Dara Biosciences, Inc. Methods of treating neurodegenerative diseases using indane acetic acid derivatives which penetrate the blood brain barrier
US9334266B2 (en) 2009-09-04 2016-05-10 The University Of Toledo Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
WO2012074980A2 (en) * 2010-12-01 2012-06-07 Dara Biosciences, Inc. Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
CA2980296A1 (en) * 2015-03-26 2016-09-29 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives
TWI712582B (zh) * 2015-10-14 2020-12-11 法商領先藥物公司 用來製備(5s,10s)-10-苄基-16-甲基-11,14,18-三側氧基-15,17,19-三氧雜-2,7,8-三噻基-12-氮二十一烷基-5-銨基(e)-3-羧基丙烯酸鹽的工業方法
US20180153860A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives
US20180153859A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype
JP7185681B2 (ja) 2017-07-28 2022-12-07 ケモセントリックス，インコーポレイティド 免疫調節化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929923A (en) * 1972-01-17 1975-12-30 Sun Research Development Process for preparation of isomers of 1-cyclohexyl-1,3,3-trimethylhydrindane
US4754043A (en) * 1985-10-03 1988-06-28 American Home Products Corporation Oxazole and thiazole naphthalenes as antiallergic agents
FR2670491B1 (fr) * 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5480896A (en) * 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
JPH1087602A (ja) * 1996-09-09 1998-04-07 Zeria Pharmaceut Co Ltd スルホンアミド誘導体、それを含有するトロンボキサン拮抗剤及び該化合物の製造中間体
WO1999011255A1 (fr) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Regulateurs du recepteur active par les agents de proliferation des peroxysomes
AU782404B2 (en) 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
DK1206457T3 (da) * 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
WO2002018355A1 (en) * 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento

Also Published As

Publication number Publication date
WO2003011842A1 (en) 2003-02-13
RU2314298C2 (ru) 2008-01-10
CA2455620A1 (en) 2003-02-13
AR036237A1 (es) 2004-08-25
HK1098125A1 (en) 2007-07-13
HRP20040076A2 (en) 2005-06-30
CY1107370T1 (el) 2012-12-19
MXPA04000599A (es) 2005-02-17
MY139541A (en) 2009-10-30
TWI345563B (en) 2011-07-21
ATE388944T1 (de) 2008-03-15
AU2002319693B2 (en) 2008-08-07
PL374383A1 (en) 2005-10-17
PT1414809E (pt) 2008-06-04
SV2003001186A (es) 2003-03-18
CN100528850C (zh) 2009-08-19
IL208891A (en) 2013-02-28
EP1414809B1 (en) 2008-03-12
DE60225561T2 (de) 2009-04-23
IL159960A0 (en) 2004-06-20
US20090047687A1 (en) 2009-02-19
HUP0700105A2 (en) 2007-09-28
US20060205723A1 (en) 2006-09-14
CA2455620C (en) 2011-12-06
NO20040356L (no) 2004-03-19
US7112597B2 (en) 2006-09-26
BR0211502A (pt) 2005-09-20
EP1414809A1 (en) 2004-05-06
HK1073653A1 (en) 2005-10-14
JP2005508308A (ja) 2005-03-31
KR20040028950A (ko) 2004-04-03
KR100956898B1 (ko) 2010-05-11
UY27392A1 (es) 2003-01-31
IL159960A (en) 2010-12-30
MA27063A1 (fr) 2004-12-20
US6828335B2 (en) 2004-12-07
CA2753329A1 (en) 2003-02-13
PE20030326A1 (es) 2003-04-16
ES2302825T3 (es) 2008-08-01
IL208891A0 (en) 2011-01-31
TWI328008B (en) 2010-08-01
AU2008237581A1 (en) 2008-11-20
NZ531351A (en) 2006-09-29
US20030216391A1 (en) 2003-11-20
US7358386B2 (en) 2008-04-15
DE60225561D1 (de) 2008-04-24
KR20090125225A (ko) 2009-12-03
TW201029979A (en) 2010-08-16
US20050075338A1 (en) 2005-04-07
NO20083411L (no) 2004-03-19
CO5560561A2 (es) 2005-09-30
DK1414809T3 (da) 2008-06-23
JP4510447B2 (ja) 2010-07-21
CN1558905A (zh) 2004-12-29
KR100987267B1 (ko) 2010-10-12
RU2004105925A (ru) 2005-07-10

Similar Documents

Publication Publication Date Title
IL208891A0 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
AU2003299790A8 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
HUP0401647A3 (en) Novel betha-phenyl-alpha-oxy propionic acid derivatives, processes for their preparation and their use in the preparation of pharmaceutically important compounds
IL161693A0 (en) N-adamantylmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation
AU2002365516A1 (en) Benzamide derivatives, processes for their preparation, and their pharmaceutical use
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
PL370244A1 (en) Dicarboxylic acid derivatives, their preparation and therapeutic use
HK1077832A1 (en) 17a-ALKYL-17ß-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE FRODUCTION THEREOF, AND USE OF SAID 17a-ALKYL-17ß-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS
HUP0103987A3 (en) Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
IL145789A0 (en) Derivatives of propionic acid, their preparation and pharmaceutical compositions containing them
HUP0301683A3 (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral indopeptidase, their intermediates, process for their preparation, pharmaceutical compositions containing them and their use
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
ZA200601991B (en) Process for the preparation of renzapride and intermediates thereof
HUP0204563A3 (en) Process for preparation of 3,3-diarylpropylamine derivatives and their intermediates and their use for preparation of pharmaceutical compositions
HUP0303751A3 (en) Use of n-phenyl-2-pyrimidineamine derivatives for preparation of pharmaceutical compositions suitable for treating mast cell-based diseases like allergic disorders
HK1080453A1 (en) Intermediates in producing phenoxyacetic acid derivatives and method of using the same
AU2002227015A1 (en) Processes and synthetic intermediates for preparing N-arylacridancarboxylic acid derivatives
HUP0402602A3 (en) Method for preparing echinocandin derivatives, their use, pharmaceutical compositions comprising thereof and their intermediates
PL359208A1 (en) New derivatives of quinosoline, method of production of new derivatives of quinosoline and pharmaceutical preparations
IL166097A0 (en) Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole preparation process and intermediates of this process their use as medicaments and pharmaceutical compositions comprising them
AU5428700A (en) Acrylic acid derivatives, use of the same and intermediates for the preparation thereof
AU2003221960A1 (en) Indane acetic acid derivatives and their use as pharmaceutical agents
IL170315A (en) Cycloalkyl-substituted alkanoic acid derivatives, pharmaceutical compositions and use thereof
AU2002246926A1 (en) 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
AU2002355044A1 (en) Process for preparation of 2-aminotetralin derivatives and intermediates thereof